Nanopore

Global Next-generation Sequencing Market Expected Growth of 20.9% During the Forecast Period, 2019-2025 - ResearchAndMarkets.com

Retrieved on: 
星期二, 十二月 24, 2019
Science, Health, Other Science, Other Health, Branches of biology, Biology, Molecular biology, Life sciences, Biotechnology, DNA sequencing, Nanotechnology, DNA, Ion semiconductor sequencing, Nanopore, Sequencing, SMRT

The NGS market is segmented based on application, technology, product & service, end user, and region.

Key Points: 
  • The NGS market is segmented based on application, technology, product & service, end user, and region.
  • On the basis of technology, the NGS market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, nanopore sequencing, and other sequencing technologies.
  • In 2018, the SBS segment accounted for the largest share of the NGS market.
  • The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

Next-generation Sequencing (NGS) Market Worth $24.4 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
星期一, 十二月 2, 2019
Branches of biology, Biology, Life sciences, Molecular biology, Biotechnology, Nanotechnology, DNA, DNA sequencing, Sequencing, Ion semiconductor sequencing, Nanopore sequencing, Nanopore

The SBS segment accounted for the largest share of the NGS market, by technology, in 2018

Key Points: 
  • The SBS segment accounted for the largest share of the NGS market, by technology, in 2018
    On the basis of technology, the NGS Services Market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, nanopore sequencing, and other sequencing technologies.
  • In 2018, the SBS segment accounted for the largest share of the market.
  • In 2018, the academic institutes & research centers segment accounted for the largest share of the NGS Services Market.
  • Get 10% Customization Research Report:
    North America accounted for the largest share of the Next-generation Sequencing Marketin 2018, followed by Europe.

Next-generation Sequencing (NGS) Market Worth $24.4 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
星期一, 十二月 2, 2019
Branches of biology, Biology, Life sciences, Molecular biology, Biotechnology, Nanotechnology, DNA, DNA sequencing, Sequencing, Ion semiconductor sequencing, Nanopore sequencing, Nanopore

The SBS segment accounted for the largest share of the NGS market, by technology, in 2018

Key Points: 
  • The SBS segment accounted for the largest share of the NGS market, by technology, in 2018
    On the basis of technology, the NGS Services Market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, nanopore sequencing, and other sequencing technologies.
  • In 2018, the SBS segment accounted for the largest share of the market.
  • In 2018, the academic institutes & research centers segment accounted for the largest share of the NGS Services Market.
  • Get 10% Customization Research Report:
    North America accounted for the largest share of the Next-generation Sequencing Marketin 2018, followed by Europe.

Global Whole Genome And Exome Sequencing Market Report 2019: Forecast to 2023 & Executive and Consultant Guides 2020 to 2024

Retrieved on: 
星期五, 十一月 1, 2019
Nanotechnology, Companies, Branches of biology, Biology, Konica Minolta, Nanopore sequencing, Molecular biology, Nanopore, Massachusetts Mutual Life Insurance Company, Minolta, Draft:Ambry Genetics

3.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS.

Key Points: 
  • 3.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS.
  • 3.3.4.1 What is Oxford Nanopore Sequencing?
  • 3.3.4.2 What can Oxford Nanopore Sequencingt be used for?
  • Human Longevity Launches Whole Genome Product, MassMutual Partnerships
    Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion

Whole Genome And Exome Sequencing Markets, 2023 - Research, Clinical, Direct to Consumer, AgriBio & Tumor - ResearchAndMarkets.com

Retrieved on: 
星期五, 十一月 1, 2019
Health, Genetics, Nanotechnology, Companies, Branches of biology, Biology, Konica Minolta, Nanopore sequencing, Molecular biology, Nanopore, Massachusetts Mutual Life Insurance Company, Minolta, Draft:Ambry Genetics

3.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS.

Key Points: 
  • 3.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS.
  • 3.3.4.1 What is Oxford Nanopore Sequencing?
  • 3.3.4.2 What can Oxford Nanopore Sequencingt be used for?
  • Human Longevity Launches Whole Genome Product, MassMutual Partnerships
    Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion

Oxford Nanopore Announces That It Has Entered Into a Non-exclusive Agreement With Caribou Biosciences for CRISPR-Cas9 Enrichment for Nanopore Sequencing

Retrieved on: 
星期四, 九月 19, 2019
Branches of biology, Biology, Life sciences, Genome editing, Biotechnology, Molecular biology, Immune system, Nanotechnology, Cas9, Nanopore sequencing, CRISPR, Nanopore

OXFORD, England, Sept. 19, 2019 /PRNewswire/ -- Oxford Nanopore and Caribou Biosciences, Inc. have entered into a non-exclusive license agreement under which Caribou has granted Oxford Nanopore a worldwide, non-exclusive license under foundational CRISPR-Cas9 intellectual property controlled by Caribou for nanopore sequencing.

Key Points: 
  • OXFORD, England, Sept. 19, 2019 /PRNewswire/ -- Oxford Nanopore and Caribou Biosciences, Inc. have entered into a non-exclusive license agreement under which Caribou has granted Oxford Nanopore a worldwide, non-exclusive license under foundational CRISPR-Cas9 intellectual property controlled by Caribou for nanopore sequencing.
  • Many teams have already been successful using this approach and Oxford Nanopore plan to release a Cas9 Sequencing Kit later in the year.
  • Timothy Gilpatrick and team demonstrated the capacity of Cas9 enrichment and long-read nanopore sequencing to thoroughly characterise cancer driver genes.
  • Cas9 enrichment with Oxford Nanopore sequencing enables scientists to cost-effectively sequence targeted regions previously not accessible; including repeat expansion, methylation, low complexity sequence and large regions of structural variation.

Oxford Nanopore Announces That It Has Entered Into a Non-exclusive Agreement With Caribou Biosciences for CRISPR-Cas9 Enrichment for Nanopore Sequencing

Retrieved on: 
星期四, 九月 19, 2019
Branches of biology, Biology, Life sciences, Genome editing, Molecular biology, Biotechnology, Nanotechnology, Immune system, Nanopore sequencing, CRISPR, Cas9, Nanopore

-Technology enables targeted sequencing for rapid, precise DNA analysis on portable or large sequencers-

Key Points: 
  • -Technology enables targeted sequencing for rapid, precise DNA analysis on portable or large sequencers-
    OXFORD, England, Sept. 19, 2019 /PRNewswire/ -- Oxford Nanopore and Caribou Biosciences, Inc. have entered into a non-exclusive license agreement under which Caribou has granted Oxford Nanopore a worldwide, non-exclusive license under foundational CRISPR-Cas9 intellectual property controlled by Caribou for nanopore sequencing.
  • CRISPR-Cas9-mediated enrichment for nanopore sequencing enables fast, simple, flexible and targeted sequencing of long regions of interest, without the need for amplification read lengths of over 100Kb have been observed to date.
  • Many teams have already been successful using this approach and Oxford Nanopore plan to release a Cas9 Sequencing Kit later in the year.
  • Timothy Gilpatrick and team demonstrated the capacity of Cas9 enrichment and long-read nanopore sequencing to thoroughly characterise cancer driver genes.

Ontera Expands Executive Leadership Team as the Nanopore Diagnostics Company Advances Towards Product Commercialization

Retrieved on: 
星期二, 九月 17, 2019
Biotechnology, Software, Nanotechnology, Health, Technology, Genetics, Nanotechnology, Bell Aliant, Ontario Northland Transportation Commission, Ontera, Nanopore, Molecular biology, Biotechnology, Telecommunications in Canada, Economy of Canada, Companies of Canada

These two new members of the Ontera leadership team will play critical roles in preparing the company for commercialization of its first device in 2021.

Key Points: 
  • These two new members of the Ontera leadership team will play critical roles in preparing the company for commercialization of its first device in 2021.
  • As vice president of product management, Mark Rose will be responsible for the development, launch and commercial activities of Onteras diagnostic product portfolio.
  • Under his leadership, Ontera will introduce its first product, which will leverage Onteras novel sample-to-answer platform for initial applications in agriculture.
  • The company aims to revolutionize diagnostics with its single-molecule detection and genome analysis platforms based on proprietary biochemistry and silicon nanopore chip-based sensors.

Global Whole Genome and Exome Sequencing Markets, 2019-2023 - Diagnostic Factors / Interpreting the Code Otherwise / Changes in Agriculture/ Fertility Technology Comes of Age / Pathogen Challenges

Retrieved on: 
星期五, 七月 19, 2019
Nanotechnology, Branches of biology, Natural sciences, Biology, Molecular biology, DNA sequencing, Nanopore sequencing, Biotechnology, Nanopore, Third-generation sequencing, DNA sequencer

3.3.2 Declining Cost of Instruments Changes Industry Structure.

Key Points: 
  • 3.3.2 Declining Cost of Instruments Changes Industry Structure.
  • 3.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS.
  • 3.3.4.1 What is Oxford Nanopore Sequencing?
  • 3.3.4.2 What can Oxford Nanopore Sequencingt be used for?

Ontera Welcomes Dr. J. Wallace Parce to Its Advisory Board

Retrieved on: 
星期三, 七月 17, 2019
Biotechnology, Technology, Health, Medical devices, Research, Nanotechnology, Genetics, Science, Nanotechnology, Nanopore, Parce, Ontera, Telecommunications in Canada

Ontera, the leader in silicon-based nanopore diagnostics, today announced the appointment of Dr. J. Wallace (Wally) Parce to its Advisory Board.

Key Points: 
  • Ontera, the leader in silicon-based nanopore diagnostics, today announced the appointment of Dr. J. Wallace (Wally) Parce to its Advisory Board.
  • Dr. Parce comes to Ontera as a respected and successful serial entrepreneur in life science technology development and commercialization.
  • Over the course of his career, he has excelled at bringing interdisciplinary teams of innovators together to launch high technology products.
  • Ontera is changing the diagnostics world by creating a suite of unique and broadly applicable platforms based on single molecule counting through silicon nanopores, said Dr. Parce.